Intrinsic Value of S&P & Nasdaq Contact Us

NEXGEL, Inc. NXGL NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score
45/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

NEXGEL, Inc. (NXGL) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.

Analysts estimate Earnings Per Share (EPS) of $-0.54 and revenue of $0.01B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-0.50 vs est $-0.54 (beat +7.4%). 2025: actual $-0.38 vs est $-0.35 (missed -8.6%). Analyst accuracy: 92%.

NXGL Analyst Ratings

Buy
1
Ratings
1 Buy
Based on 1 analysts giving stock ratings to NEXGEL, Inc. in the past 3 months
Rating breakdown
Buy
1 100%
100%
Buy
1 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

EPS Estimates — NXGL

92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual –$0.50 vs Est –$0.54 ▲ 8.0% off
2025 Actual –$0.38 vs Est –$0.35 ▼ 7.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

Revenue Estimates — NXGL

98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.009B vs Est $0.009B ▲ 0.6% off
2025 Actual $0.011B vs Est $0.012B ▼ 3.9% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message